Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

By Lips E.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 827-836

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome

By Witzel Isabell   Milde-Langosch Karin   Wirtz Ralph   Roth Claudia   Ihnen Maike   Mahner Sven   Zu Eulenburg Christine   Jänicke Fritz   Müller Volkmar  

Journal of Cancer Research and Clinical Oncology, Vol. 136, Iss. 11, 2010-11 ,pp. : 1709-1718

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican Population of locally advanced breast cancer patients

By Muñoz-Gonzalez David   Zeichner-Gancz Isabel   Candelaria Myrna   Ramirez-Ugalde Maria   Perez-Sanchez Manuel   Cervantes-Vazquez Guadalupe   Cantu-de Leon David   Mora-Tizcareño Arcelia   Leonor-Ortíz Julio  

Medical Oncology, Vol. 22, Iss. 1, 2005-03 ,pp. : 23-28

Humana Press, Inc

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

By          

Experimental and Therapeutic Medicine, Vol. 3, Iss. 1, 2012-01 ,pp. : 66-71

Spandidos Publications

Access to resources Recommend Favorite